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An automated radiosynthesis of carbon-11 positron emission tomography
radiotracer [11C]UCB-J for imaging the synaptic density biomarker synaptic
vesicle glycoprotein SV2A was established using Synthra RNPlus synthesizer.
Commercially available trifluoroborate UCB-J analogue was used as a radio-
labelling precursor, and the desired radiolabelled product was isolated in 11 ±
2% (n = 7) nondecay corrected radiochemical yield and formulated as a 10%
EtOH solution in saline with molar activities of 20 to 100 GBq/μmol. The
method was based upon the palladium(0)-mediated Suzuki cross-coupling
reaction and [11C]CH3I as a radiolabelling synthon. The isolated product was
cGMP compliant as demonstrated by the results of quality control analysis.
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1 | INTRODUCTION
Synapses are specialized structures in the brain, which
mediate a functional interaction between two neurons
or between a neuron and another cell type.1 They are
involved in processes of higher brain functions such
as information processing (eg, thinking) or changes
with experience (eg, learning). As such, synapses
are targets of many psychoactive drugs and can
become defective in neurological diseases as well as
psychiatric disorders.2-6 While the synaptic density
can be used as a quantitative biomarker of synaptic
pathology, in human subjects, this can only be deter-
mined through a post mortem autopsy or surgical
resection.7
Abbreviations: PET, positron emission tomography; SV2A, synaptic
vesicle glycoprotein 2A; LCMS, liquid chromatography mass
spectrometry; HPLC, high-pressure liquid chromatography; TLC, thin-
layer chromatography.
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Recently developed is a noninvasive alternative
using positron emission tomography (PET), which for
the first time enables the quantification of synaptic
density in vivo. This is achieved by radiotracers selec-
tive to synaptic vesicle glycoprotein SV2A, a trans-
membrane protein expressed ubiquitously in secretory
vesicles in all brain areas.8 Arising from several struc-
tural scaffolds related to the antiepileptic drug
levetiracetam (LEV, 1; Figure 1)9 the carbon-11 radio-
labelled UCB-J analogue ([11C]2; Figure 1) has been
shown to have excellent in vitro and in vivo properties
for imaging SV2A from both preclinical and clinical
studies.7,10
Therefore, to undertake clinical SV2A PET studies at
our centre, our objective was to establish a manufactur-
ing method for [11C]UCB-J for which a radiosynthesis
method has been developed.7,10,11 Herein, we report
development of the fully automated and cGMP compliant
radiosynthesis of [11C]UCB-J using Synthra RNPlus auto-
mated radiosynthesizer.
2 | MATERIALS AND METHOD
2.1 | General techniques
All anhydrous solvents were purchased from Aldrich,
Alfa Aesar, or Acros and used as received unless oth-
erwise noted. Water for injection was purchased from
Braun and sodium chloride 0.9% w/v injection BP
from Kent Pharmaceuticals. Water for cleaning of the
synthesizer was Millipore (18.2 MΩ), and water used
for the radiosynthesis was BP grade. The radiolabelling
precursor and the reference material were obtained
from UCB, Belgium. The Sep-Pak Classic C18 car-
tridges were purchased from Waters and the empty
3-mL SPE columns with frits Chromabond from
Macherey-Nagel. Ethanol for injection was purchased
from Merck.
Radiochemical yields for the product were based on
[11C]CH3I and decay corrected unless otherwise stated.
2.2 | Radiosynthesis of [11C]UCB-J on
Synthra RNPlus
Prior to each production, the automated synthesizer was
cleaned using H2O and absolute EtOH and acetone. The
[11C]CH3I delivery line was tested for flow and leak tight-
ness. The GE MeI module was preconditioned (heating
followed by the cooling of the Ni- and porapak ovens)
using automated PREPARATION stage of the module.
The automated Synthra RNPlus set up was as follows
(see Figure 2):
A3: 0.3 mL DMF:H2O 8:1 v/v
B3: 1.6 mL 1M aq HCl
C1: 13 mL NaCl 0.9% BP
C2: 1.4 mL absolute EtOH
C3: 15 mL H2O for injection
SPE: 50 mL H2O for injection
C18: Classic cartridge, conditioned with 5 mL EtOH,
10 mL H2O, then 2 mL air
Filter frit: filled with 3.2 mL HPLC eluent, placed
between V47 and V25
HPLC: Semipreparative column Gemini-NX C18
250x10 mm, 5 μm, 100 Å, eluting with 65% 100 mM
ammonium formate pH 9.2 and 35% MeCN; flow
8 mL/min, λ = 254 nm
REACTOR 1: 1.6-1.7 mg (R)-trifluoro(4-((2-oxo-4-(3,-
4,5-trifluorophenyl)pyrrolidin-1-yl)methyl)pyridin-1-ium-
3-yl)borate (UCB-J precursor) in 54 μL MeOH and 22 μL
1M aq HCl
REACTOR 2: 28 μL potassium carbonate aqueous
solution (4-5 mg in 280 μL H2O), 244 μL bis
(dibenzylideneacetone)palladium(0) solution in anhy-
drous DMF (1.0-1.5 mg Pd (dba)2 in 488 μL DMF), 200
μL tris(o-tolyl)phosphine solution in anhydrous DMF
(2.0-2.5 mg P(o-Tol)3 in 500 μL DMF), and 500 μL anhy-
drous DMF
PRECURSOR ACTIVATION: Precursor activation is a
step that commences at the same time as the cyclotron
target bombardment starts and precedes the oxidative
insertion of Pd to carbon-halide bond. The activation of
the precursor is achieved by placing the precursor into
the reactor 1, adding MeOH and HCl, and stirring the
mixture over 30 minutes at ambient temperature. The
mixture is then dried in the stream of He and under vac-
uum and finally only vacuum after which it is redissolved
in DMF:H2O (0.3 mL, 8:1 v/v) and transferred from reac-
tor 1 to reactor 2.
[11C]CO2 is produced via the nuclear reaction
14N
(p,α)11C using GE PETtrace cyclotron from 0.5% O2
enriched N2. Typically bombardment was performed at
35 μAh over 40 to 45 minutes. The produced [11C]CO2
FIGURE 1 Positron emission tomography radiotracers for
imaging SV2A, a biomarker of synaptic density and the
radiosynthetic strategy used for preparation of [11C]UCB-J
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was then converted to [11C]CH3I using a GE MeI module
via reduction to [11C]CH4 using a Shimalite nickel cat-
alyst/column followed by condensation reaction of [11C]
CH4 with I2 at 720C during the recirculation after which
[11C]CH3I is trapped on the Porapak and released upon
heating. The produced [11C]CH3I was received in the
reactor 2 of the Synthra RNPlus automated module and
bubbled through the mixture containing base, ligand,
and catalyst solution and DMF (see REACTOR 2) at –
15C for 4 to 7 minutes during the number of counts per
second in the reactor 2 peaked. The reaction mixture was
then heated to 30C for 3 minutes to allow for oxidative
insertion of Pd to carbon-halogen bond to occur. The
activated precursor was then added (see PRECURSOR
ACTIVATION) as DMF:H2O solution, and the reaction
mixture was allowed to heat to 100C over 5 minutes.
After this time, the reaction mixture is allowed to cool to
30C and then quenched with HCl from B3 and loaded
onto the high-pressure liquid chromatography (HPLC)
loop via the syringe and by passing the mixture through
the SPE column with frit containing eluent. The semi-
preparative purification finally yields desired [11C]UCB-J,
which is collected in the SPE flask containing H2O and
then trapped on the C18 Classic cartridge. The product is
washed with H2O and then eluted with EtOH and formu-
lated as a saline solution and dispensed in the grade A
isolator by passing the mixture through the sterile filter.
2.3 | QC analysis
Prerelease QC of [11C]UCB-J took approximately
30 minutes and was performed as described previously.12
Release criteria and the results of three typical produc-
tion experiments are summarized in Table 2. The pH of
the product was determined using Seven Excellence pH
meter, and the visual check was performed behind a
lead-shielded window. Chemical and radiochemical iden-
tity and purity were analysed by analytical radio-HPLC
on the ThermoFisher Ultimate 3000 HPLC system using
Waters XBridge C18 reverse phase column (3.5 μm,
100×3.0 mm) eluting with 30% MeCN in 10 mM sodium
phosphate at 0.8 mL/min. The HPLC system was
equipped with an UV detector (λ = 258 nm) and EG&G
Ortec Amplifier 0.70 kV radioactivity detector. The radio-
chemical purity was determined as the percentage of the
[11C]UCB-J peak on the radio-chromatogram. Radio-
chemical identity was confirmed and assessed by compar-
ison of the retention time of the [11C]UCB-J radioactive
peak to that of the UCB-J reference standard peak in the
coinjection sample. The chemical amount of [11C]UCB-J
and cold impurities was determined by quantification
and relative comparison of the corresponding UV absor-
bance peaks of the QC sample and reference standards of
known concentration. The acceptance limit of 10 μg for
UCB-J in the injection dose was established based on the
selected animal toxicity study taking into account guide-
line on setting permitted daily exposure by European
Medical Agency. The maximal allowable injection vol-
ume (Vmax) of radiotracers produced at the Wolfson Brain
Imaging Centre (WBIC) is by default limited to 10 mL
and was calculated based on the chemical amount of
[11C]UCB-J and cold impurities relative to their specifica-
tion Vmax = 10 μg/specification of [11C]UCB-J found in a
QC sample (μg/mL). Molar activity (Am) was calculated
FIGURE 2 Automated radiosynthesizer Synthra RNPlus as the platform for the radiosynthesis of [11C]UCB-J
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as the ratio of radioactivity in GBq and the amount of
UCB-J (μmol) at the time of anticipated application
(20 min after the EOS). The integrity of the Acrodisc
Supor Membrane filter (0.2 μm, 25 mm) was tested using
the filter integrity (ie, bubble point) test. Sterility, bacte-
rial endotoxins, radionuclidic identity, and residual sol-
vent analyses of the product were assessed as the
postrelease tests. Endotoxin content in [11C]UCB-J doses
was measured with the Charles River Laboratories Endo-
safe Portable Test System. Residual solvent analysis was
performed on Thermo Focus Gas Chromatograph
equipped with the Thermo column (60×1.80×0.8500) and a
flame ionization detector. Radionuclidic identity was
determined by measuring [11C]UCB-J activities in tripli-
cate at different time points (5-min intervals) using
Veenstra VDC-505 radioisotope dose calibrator, and the
half-life was calculated as per the following: t1/2 = –ln2
((t2 – t1)/ln(A2/A1)), whereby t1 and t2 are two different
times and A1 and A2 are radioactivity measured at times
t1 and t2, respectively.
3 | RESULTS AND DISCUSSION
The radiosynthesis of [11C]UCB-J is based on the applica-
tion of the palladium(0)-mediated Suzuki cross-coupling
reaction between the carbon-11 methyliodide ([11C]CH3I)
and trifluoroborate precursor 3 (Figure 1).7,10,11,13,14 Ini-
tially explored method employed a more common Suzuki
reacting partner, ie, the corresponding boronic acid15 (eg,
4 in Scheme 1) as a radiolabelling precursor; however,
the boronic acid precursor 4 proved to be unstable upon
storage resulting in poor reproducibility and unreliable
radiochemical yields. Further investigation indicated that
while trifluoroborate 3 can be used as a radiolabelling
precursor for [11C]UCB-J, the actual reacting specie is the
boronic acid, thus necessitating a need for a mixture of
trifluoroborate 3 and 3-10% of the boronic acid 4 to be
present in the reaction vessel.11,14
While the application of the mixture improved repro-
ducibility of the method, it made it non-GMP compliant
for which reason Onega and coworkers11 developed an
improved protocol whereby the boronic acid was formed
in situ by treatment of trifluoroborate 3 with 1M HCl
(Scheme 1).
In our hands, in situ preparation of boronic acid
worked sluggishly (Table 1 and Table S1). Based on the
method developed by Onega et al,11,14 hydrochloric acid
SCHEME 1 Radiosyntheses of [11C]UCB-J via direct Suzuki
cross-coupling of borate precursor 3 or via the boronic acid
intermediate
TABLE 1 Various conditions for the in situ preparation of boronic acid precursor 4
Entry Conditions Concentration, mg 3 in HCl: MeOH Time, min LCMS Conversion, %
1 HCl in dioxane 2 mg in 0.25:2 mL 40 0
2 HCl in MeOH 3 mg in 0.5:3 mL 40 24
3 HCl in H2O 1.9 mg in 0.5:2 mL 190 39
a
4 HCl in H2O 1.8 mg in 22:54 μL 32 0
5 HCl in H2O 1.8 mg in 0.2:0.5 mL 37 38
b
aAq. HCl added in 2×0.25 mL portions.
bReaction performed with the crude material.
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was employed and reaction progress monitored by the
liquid chromatography-mass spectrometry (LCMS) using
HCl in different solvents. The application of HCl in diox-
ane gave none of the desired boronic acid 4 (entry 1). In
methanolic HCl, a 24% conversion by LCMS was
achieved after 40 minutes (entry 2). Using the aqueous
solution of HCl (c=1 M) afforded desired 4 in maximum
39% LCMS conversion after repeated addition of the acid
and extended reaction time. We speculated that it was
the concentration of the reaction mixture, which deter-
mined the conversion to the desired boronic acid 4. To
test this, the aqueous HCl used by Onega et al11 was
employed at 63 and 6.3 mM total reaction concentrations
to afford 0% and 38% LCMS conversion over the same
period of time, respectively. This suggested that complete
conversion to boronic acid was not essential; however,
the mixture of unreacted trifluoroborate 3 and boronic
acid 4 was required to be free from MeOH/HCl prior to
Suzuki cross-coupling reaction. The smaller volume of
solvents (MeOH/HCl) would be quicker to remove; thus,
we set out to use 63 mM concentration and perform the
radiochemical step next. To implement an automated
method for [11C]UCB-J manufacture, we decided to use a
Synthra RNPlus module (Figure 2).
While the main disadvantage of using Synthra
RNPlus module, which is intended for radioactive fluori-
nations, was a requirement for the external source of
[11C]CH3I, the module presented several advantages par-
ticular to the case of [11C]UCB-J as follows: (a) two reac-
tors that are ideal for the in situ preparation of the
reacting precursor 3/4 and subsequent Pd-mediated
Suzuki coupling; (b) size of the reactors which allows for
larger volumes particularly for the injection of crude
reaction mixture onto semipreparative HPLC column;
spare valves that allow for introduction of external gases,
eg, [11C]CH3I; (d) spare connection points for the filter
frit and the SPE cartridge to allow filtration of the crude
mixture and product formulation; and (e) easily replace-
able HPLC injection loop and corresponding injection
syringe to allow for 5-mL injection volumes.
The availability of two reactors proved beneficial for
two reasons. It was quickly determined that the
activation/hydrolysis of precursor 3 cannot be per-
formed in the same reactor as the subsequent coupling,
presumably due to the deactivation of Pd-phosphine
complex in the presence of acid. Furthermore, consider-
ing the mechanism of classical Suzuki cross-coupling
reaction (Scheme 2), Pd-complex insertion into the
carbon-halide bond of [11C]CH3I (I to II), ie, oxidative
addition, must precede transmetallation (III to IV) for
which reason the activated precursor 3/4 is added once
the [11C]CH3I trapping is complete and reactants
allowed time for oxidative insertion. Allowing the oxi-
dative insertion step to occur ahead of the addition of
boron analogue enabled the successful conversion to
the product as has been demonstrated previously for
other Suzuki transformations.16
In an initial radiosynthesis attempt, 35% of the [11C]
CH3I was converted to [
11C]UCB-J as assessed by radio-
HPLC using the following setup: reactor 1 was charged
with the precursor 3/4, MeOH and 1M aq HCl; reactor
2 was charged with Pd(0)-catalyst, (o-Tol)3P and the base
K2CO3 (Figure 2). After 30 minutes of acid-promoted
hydrolysis of 3, the activated precursor 3/4 was dried in
the stream of He over 10 minutes. At the same time,
freshly produced [11C]CH3I was trapped in the mixture
of catalyst, ligand, and base in total volume of 0.5 mL
and then heated to 30 C over 3 minutes after which
time activated 3/4 in DMSO was added and reaction
proceeded at 130C. In a repeated follow-up attempt, 0%
conversion to [11C]UCB-J was observed. This discrep-
ancy in the observed conversion to the product led to
the detailed investigation of reaction parameters and
helped identify critical aspects of the radiosynthesis
(Table 2).
TABLE 2 Critical parameters in the radiosynthesis of [11C]












Dried over molecular sieves.
Bottle replaced every 2
weeks
3 Trapping of [11C]
CH3I
Reaction volume in reactor 2





Using 5 mL injection loop
and diluting the reaction
mixture with eluent and
filtering prior to injection
5 Quality of [11C]CH3I Using [
11C]CH3I with high
molar activity
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The most important factor determining the success of
the reaction proved to be efficient removal of HCl/MeOH
from the activated precursor 3/4. Thus, solvent removal
using a stream of helium only gave variable results for
which reason solvent removal under vacuum in the
stream of helium was employed. Using the material
activated following this method warranted reliable results
in the subsequent cross-coupling step. DMF is a hygro-
scopic solvent, and reliable radiosynthesis of [11C]UCB-J
was achieved if the bottle was replaced every 2 weeks.
While the exact reasons for this requirement remain
unclear, it was proposed that the moisture from the DMF
could affect the reaction success. Next important
parameter, which improved the trapping efficiency, was
the volume of the reaction mixture. Having a large
10-mL reactor required the total volume of the reaction
mixture to be increased to 1.1 mL (from 0.5 mL
previously reported by others). The reliable radio-
synthesis was achieved however, only if the reactor was
pressurized immediately after the [11C]CH3I trapping,
significantly limiting the radioactivity losses (Table 2).
Another varying factor was reliable loading of the crude
reaction mixture onto the HPLC loop. The crude reaction
mixture due to some Pd particles present was filtered
prior to injection onto the semipreparative HPLC
column. Several different filters (eg, membrane frits)
were employed for this purpose but resulted in blocking.
To overcome complications caused by small filter pores,
filter frit in a syringe (empty SPE column with frit) used
by Onega and coworkers11 was applied. While this
eliminated the majority of Pd-particles present in the
reaction mixture, it led to varying amounts of air in the
lines between V47/V25 and the HPLC syringe. To avoid
this, the SPE column with frit was prefilled with the elu-
ent and the loading onto HPLC loop achieved in two
stages: firstly, half of the eluent was withdrawn and dis-
carded, which was followed by the insertion of the reac-
tor needle back into the reaction solution and second
FIGURE 3 Ultraviolet and
radio traces for the optimized
radiosynthesis of [11C]UCB-J on
Synthra RNPlus module. Note
that for clarity, Ultraviolet (UV)
trace is increased by threefold
magnitude
SCHEME 2 Proposed mechanism of Pd-mediated Suzuki cross-coupling reaction to obtain [11C]UCB-J
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withdrawal of both the crude mixture and the remaining
eluent.
Following closely these requirements, conversions of
up to 90% were reproducibly achieved. The
radiosynthesis was successfully programmed, and typi-
cal automated profile is depicted in Figure 3. The total
synthesis time from the end of [11C]CH3I production
was ~35 minutes. The irradiation and the [11C]CH3I
typically required ~55 minutes. Typically starting
between 10 and 16 GBq of [11C]CH3I, between 0.8 and
1.4 GBq of [11C]UCB-J was produced in the customer
vial as a 10% EtOH solution in saline and with molar
activities of 20 to 100 GBq/μmol. The nondecay
corrected radiochemical yield was 11 ± 1% (n = 7) and
if decay corrected 35 ± 4% (n = 7). The QC analysis of
the produced [11C]UCB-J indicated that the product
conforms to cGMP conditions as demonstrated by the
summarized QC data in Table 3.
4 | CONCLUSIONS
In summary, reproducible radiosynthesis of [11C]UCB-J
using the Synthra RNPlus automated synthesizer has
been achieved with RCY at end of synthesis comparable
to that reported and in compliance with the cGMP regu-
lations. Several modifications to both the reaction condi-
tions (eg, preactivation of the precursor) and the Synthra
RNPlus module (eg, external delivery of [11C]CH3I) were
required to allow for a reliable production protocol and
led to identification of critical reaction parameters. This
in turn allows for the implementation of the described
production protocol in other clinical PET centres for rou-
tine manufacturing of [11C]UCB-J.
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Appearance Clear colourless solution Confronts Confronts Confronts
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≤1.5 μg/dose 1.44 1.38 1.00
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